RPRX Royalty Pharma Plc
Company Analysis
Latest News
🔴 Royalty Pharma is trading 4.3% down in pre-market with U.S. futures pointing lower
Royalty Pharma is trading 4.31% lower at $61.00, with no new company-specific announcement identified for October 23. - Supplied price context lists the...
🔴 Royalty Pharma is trading 4.51% down in pre-market amid broad market weakness
Royalty Pharma is trading 4.51% down at $59.35 in pre-market, with broad-market pressure the likeliest available explanation, though no direct link was...
🟢 Royalty Pharma is trading 4.17% up today with possible support from healthcare-sector strength
Royalty Pharma is trading at $58.93, up 4.17%, with no clear company-specific catalyst; healthcare-sector strength may have helped. - Its latest listed...
🟢 Royalty Pharma is trading 4.11% up in pre-market; catalyst unconfirmed
Royalty Pharma is trading 4.11% higher in pre-market at $60.00, with the reason unconfirmed. - The comparison is with the October 1 close of $57.63; the alert...
🟢 Royalty Pharma is trading 9.19% up in pre-market with no clear overnight catalyst
Royalty Pharma is trading 9.19% up at $64.00 in pre-market, based on the provided pre-market price, with no clear overnight announcement explaining the...
Novartis's Heart Drug Flop Erases $2 Billion From Royalty Pharma — But Does the Deal Structure Limit the Pain?
Shares of Royalty Pharma sank 6.5% to $59.81 after Novartis revealed that pelacarsen — a drug designed to lower a cholesterol-like blood particle called Lp(a)...
🔴 Royalty Pharma is trading 6.5% down today after pelacarsen failed HORIZON’s primary endpoint
Royalty Pharma is trading 6.5% down at $59.81 (-6.49%) after Novartis announced on September 4, 2026, that pelacarsen failed to meet the primary endpoint in...
🔴 Royalty Pharma is trading 4.6% down in pre-market after pelacarsen failed HORIZON’s primary endpoint
Royalty Pharma is trading 4.6% down at $61.03 after Novartis’ pelacarsen failed to meet the primary endpoint in the HORIZON Phase 3 cardiovascular outcomes...
Royalty Pharma loses pelacarsen upside, as Novartis Phase 3 trial fails
Novartis’ Phase 3 HORIZON trial for the cardiovascular drug pelacarsen failed to meet its primary endpoint. The study involved more than 8,300 patients. It...
🔴 Royalty Pharma is trading 6% down in after-hours trading with no clear company-specific catalyst
Royalty Pharma is trading at $60.15 (-5.96%) after no clear company-specific announcement was identified for September 4, 2026. • Broader markets weakened,...
Royalty Pharma's second quarter Portfolio Receipts beat estimates, prompting a raised FY2026 outlook.
Royalty Pharma reported second quarter Portfolio Receipts of $773 million, a 6% increase year-over-year, driven by strong growth in its core Royalty Receipts....
Royalty Pharma Plc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Royalty Pharma is expected to report Q2 2026 consensus Portfolio Receipts of $758.9 million and earnings per share of $1.27, with the stock currently trading...
🔴 Royalty Pharma is trading 4.4% down today after an after-hours earnings update
Royalty Pharma is trading 4.4% down at $55.88 in after-hours trading following the release of a fresh company update or earnings report after the closing...
Royalty Pharma bets $425M on AstraZeneca heart drug, targeting $5B market
Royalty Pharma plc agreed to acquire a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million. The agreement includes an...
🟢 Royalty Pharma is trading 4% up today on healthcare sector strength
Royalty Pharma is trading 4% up today at $58.56, outperforming a weak broader market where major indices are trading lower. • The move is tied to a rally in...
🟢 RPRX is trading 5.2% up today on positioning and bullish analyst sentiment
RPRX is trading at $59.89 (up 5.2%) in pre-market on positioning and bullish analyst sentiment following a recent pullback. • No fresh earnings, FDA, M&A, or...
Royalty Pharma's first quarter 2026 Portfolio Receipts of $925M beat estimates, prompting a raised full-year outlook.
Royalty Pharma reported first quarter 2026 Portfolio Receipts of $925 million, representing 10% year-over-year growth, driven by strong performance from key...
Royalty Pharma Plc Q1 2026 Earnings Preview: What Analysts Expect on May 06, 2026
Consensus estimates for Royalty Pharma (RPRX) ahead of its May 6, 2026, earnings report stand at $742.00 million in revenue and $1.22 in EPS, with the current...